By elucidating the role of TMB in influencing the response to PD-1/PD-L1 inhibitors, we hope to provide a more robust foundation for their utilization in the treatment of advanced NSCLC, potentially leading to more personalized treatment strategies and improved clinical outcomes. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.